In patients at high bleeding risk who had undergone percutaneous coronary intervention (PCI), 1 month of dual antiplatelet therapy (DAPT) was associated with a similar rate of major adverse cardiac or cerebral events but a lower bleeding risk than a longer duration of DAPT, even in patients undergoing complex PCI, a new analysis of the MASTER DAPT study shows.
The results of this subgroup analysis of complex PCI cases were presented by Pascal Vranckx, MD, Hartcentrum Hasselt, Belgium, at the Congress of European Association of Percutaneous Cardiovascular Interventions (EuroPCR 2022), being held this week in Paris.
The findings were also simultaneously published online in the European Heart Journal.
"These latest results show that, regardless of PCI-complexity, the discontinuation of DAPT at a median of 34 days compared with continuation of treatment for a median of 193 days [6.5 months] after PCI was consistently associated with similar rates of net adverse clinical events and major adverse cardiac or cerebral events and a lower rate of major or clinically relevant nonmajor bleeding," Vranckx reported.
"Results remained consistent with an alternative complex PCI definition, and in complex PCI and/or ACS as well as complex PCI and ACS," he added.
Vranckx explained that the main
